Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Gross Margin (2019 - 2021)

VYNE Therapeutics' Gross Margin history spans 3 years, with the latest figure at 230.77% for Q4 2021.

  • For Q4 2021, Gross Margin fell 31831.0% year-over-year to 230.77%; the TTM value through Dec 2021 reached 259.61%, down 35298.0%, while the annual FY2021 figure was 259.61%, 35298.0% down from the prior year.
  • Gross Margin reached 230.77% in Q4 2021 per VYNE's latest filing, up from 688.72% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2019 to a low of 688.72% in Q3 2021.
  • Average Gross Margin over 3 years is 87.94%, with a median of 84.51% recorded in 2020.
  • Peak YoY movement for Gross Margin: tumbled -1246bps in 2020, then tumbled -77737bps in 2021.
  • A 3-year view of Gross Margin shows it stood at 100.0% in 2019, then dropped by -12bps to 87.54% in 2020, then crashed by -364bps to 230.77% in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Gross Margin are 230.77% (Q4 2021), 688.72% (Q3 2021), and 169.49% (Q2 2021).